<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809262</url>
  </required_header>
  <id_info>
    <org_study_id>1222.3</org_study_id>
    <nct_id>NCT01809262</nct_id>
  </id_info>
  <brief_title>Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Single Dose Preliminary Dose-ranging and Safety in Patients With COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Primary objective: To investigate bronchodilator effect and safety of single doses of BI 1744
      CL inhaled via Respimat inhaler, Secondary objective: to characterize pharmacokinetics of BI
      1744 CL. Olodaterol dose 40 mcg was investigated only in the open-label extension part for
      additional PK assessments which are not defined as primary or secondary endpoints.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) at 24 Hours After a Single-dose of Study Treatment</measure>
    <time_frame>24 hours post-dosing</time_frame>
    <description>Forced expiratory volume in one second (FEV1) at 24 hours after a single-dose of study treatment. Means are adjusted with test-day baseline, patient, treatment, and period as fixed effects. Test-day baseline value was defined as the value at 10 minutes before inhalation of study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC 0 - 3 Hours</measure>
    <time_frame>-10 minutes (min), 30min, 1 hour (h), 2h and 3h post-dosing</time_frame>
    <description>The FEV1 AUC was calculated as the area under the curve above zero as the horizontal axis from zero time to 3 hours, using the trapezoidal rule divided by 3 hours to give the results in litres. The test-day baseline (defined as the pulmonary function test (PFT) at 10 minutes before inhalation of study medication) was assigned to time zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC 0 - 12 Hours</measure>
    <time_frame>-10 minutes (min), 30min, 1 hour (h), 2h, 3h, 4h, 6h, 8h, 10h and 12h post-dosing</time_frame>
    <description>The FEV1 AUC was calculated as the area under the curve above zero as the horizontal axis from zero time to 12 hours, using the trapezoidal rule divided by 12 hours to give the results in litres. The test-day baseline (defined as the pulmonary function test (PFT) at 10 minutes before inhalation of study medication) was assigned to time zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC 0 - 24 Hours</measure>
    <time_frame>-10 minutes (min), 30min, 1 hour (h), 2h, 3h, 4h, 6h, 8h, 10h, 12h, 14h, 22h, 23h and 24h post-dosing</time_frame>
    <description>The FEV1 AUC was calculated as the area under the curve above zero as the horizontal axis from zero time to 24 hours, using the trapezoidal rule divided by 24 hours to give the results in litres. The test-day baseline (defined as the pulmonary function test (PFT) at 10 minutes before inhalation of study medication) was assigned to time zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC 12 - 24 Hours</measure>
    <time_frame>12h, 14h, 22h, 23h and 24h post-dosing</time_frame>
    <description>The FEV1 AUC was calculated as the area under the curve above zero as the horizontal axis from 12 hours to 24 hours, using the trapezoidal rule divided by 12 hours to give the results in litres. The test-day baseline (defined as the pulmonary function test (PFT) at 10 minutes before inhalation of study medication) was assigned to time zero.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 From 0 to 3 Hours</measure>
    <time_frame>0 to 3 hours post-dosing</time_frame>
    <description>Peak FEV1 was defined as the maximum values of FEV1 from 0 to 3 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Forced Vital Capacity (FVC) From 0 to 3 Hours</measure>
    <time_frame>0 to 3 hours post-dosing</time_frame>
    <description>Peak FVC was defined as the maximum values of FVC from 0 to 3 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Peak Bronchodilator Response</measure>
    <time_frame>0 to 3 hours post-dosing</time_frame>
    <description>A bronchodilator response was considered to have been achieved if an FEV1 measurement of at least 12% greater than the test-day baseline value was recorded at any time during the first 3 hours of observation after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Onset of Response</measure>
    <time_frame>0 to 3 hours post-dosing</time_frame>
    <description>Onset of the bronchodilator response after a single dose of study treatment was defined as the linear interpolation of the time of the first bronchodilator response and the time of the observation just prior to the first bronchodilator response (even if that is the baseline observation). If none of the FEV1 values in the first 3 hours after dosing exceeded 12% of the pre-dose value, then the onset was set to 3 hours plus 1 minute.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Rescue Medication on a Test-day</measure>
    <time_frame>Visits 1,2,4,5,6</time_frame>
    <description>Number of Patients Requiring Rescue Medication on a Test-day. Salbutamol inhalation aerosol MDI (Ventolin®, 100 μg/actuation) was provided for use as rescue medication. Administration of rescue medication can occur at any point during the pulmonary function testing as deemed necessary by the patient or the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</measure>
    <time_frame>2 weeks</time_frame>
    <description>Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Testing: Average Change From Baseline of Potassium and Calcium</measure>
    <time_frame>Baseline and Visit 6</time_frame>
    <description>Laboratory testing: Average change from baseline of potassium and calcium measured on test-days</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>olodaterol 2 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olodaterol 5 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olodaterol 10 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olodaterol 20 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olodaterol 40 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>solution for inhalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>solution for inhalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of 5 mcg</intervention_name>
    <description>solution for inhalation</description>
    <arm_group_label>olodaterol 5 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of placebo</intervention_name>
    <description>solution for inhalation</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of 40 mcg</intervention_name>
    <description>solution for inhalation</description>
    <arm_group_label>olodaterol 40 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of 20 mcg</intervention_name>
    <description>solution for inhalation</description>
    <arm_group_label>olodaterol 20 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of 2 mcg</intervention_name>
    <description>solution for inhalation</description>
    <arm_group_label>olodaterol 2 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>single dose of 10 mcg</intervention_name>
    <description>solution for inhalation</description>
    <arm_group_label>olodaterol 10 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of chronic obstructive pulmonary disease

          2. Smoking history of more than 10-pack years

        Exclusion criteria:

          1. History of asthma, allergic rhinitis, myocardial infarction or unstable of
             life-threatening cardiac arrhythmias

          2. Marked baseline prolongation of QT/QTc interval
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1222.3.1 Atrium medisch centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2013</study_first_submitted>
  <study_first_submitted_qc>March 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2013</study_first_posted>
  <results_first_submitted>March 28, 2014</results_first_submitted>
  <results_first_submitted_qc>May 27, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 30, 2014</results_first_posted>
  <last_update_submitted>May 27, 2014</last_update_submitted>
  <last_update_submitted_qc>May 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A Pharmacokinetic sub-study to characterise the pharmacokinetics of 2 μg to 20 μg Olodaterol was planned in a subset of 18 patients. After preliminary evaluation of the data, an open-label extension was planned to investigate the safety, tolerability, and pharmacokinetics of single doses of 40 μg Olodaterol in the 18 patients of the PK sub-study.</recruitment_details>
      <pre_assignment_details>This was a randomised, Double-Blind, Placebo-Controlled, 5-Way crossover trial. Each treatment was only administered once in a single dose with a washout period of at least 14 days between treatments.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo / Olo 2mcg / Olo 20mcg / Olo 5mcg / Olo 10mcg</title>
          <description>Patients were administered matching Placebo in the first period, Olodaterol 2 mcg qd in the second period, Olodaterol 20 mcg qd in the third period, Olodaterol 5 mcg qd in the fourth period and Olodaterol 10 mcg qd in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P2">
          <title>Placebo / Olo 20mcg / Olo 2mcg / Olo 10mcg / Olo 5mcg</title>
          <description>Patients were administered matching Placebo in the first period, Olodaterol 20 mcg qd in the second period, Olodaterol 2 mcg qd in the third period, Olodaterol 10 mcg qd in the fourth period and Olodaterol 5 mcg qd in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P3">
          <title>Olo 2mcg / Olo 5mcg / Placebo / Olo 10mcg / Olo 20mcg</title>
          <description>Patients were administered Olodaterol 2 mcg qd in the first period, Olodaterol 5 mcg qd in the second period, matching Placebo in the third period, Olodaterol 10 mcg qd in the fourth period and Olodaterol 20 mcg qd in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P4">
          <title>Olo 2mcg / Placebo / Olo 5mcg / Olo 20mcg / Olo 10mcg</title>
          <description>Patients were administered Olodaterol 2 mcg qd in the first period, matching Placebo in the second period, Olodaterol 5 mcg qd in the third period, Olodaterol 20 mcg qd in the fourth period and Olodaterol 10 mcg qd in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P5">
          <title>Olo 5mcg / Olo 2mcg / Olo 10mcg / Placebo / Olo 20mcg</title>
          <description>Patients were administered Olodaterol 5 mcg qd in the first period, Olodaterol 2 mcg qd in the second period, Olodaterol 10 mcg qd in the third period, matching Placebo in the fourth period and Olodaterol 20 mcg qd in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P6">
          <title>Olo 5mcg / Olo 10mcg / Olo 2mcg / Olo 20mcg / Placebo</title>
          <description>Patients were administered Olodaterol 5 mcg qd in the first period, Olodaterol 10 mcg qd in the second period, Olodaterol 2 mcg qd in the third period, Olodaterol 20 mcg qd in the fourth period and matching Placebo in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P7">
          <title>Olo 10mcg / Olo 20mcg / Olo 5mcg / Placebo / Olo 2mcg</title>
          <description>Patients were administered Olodaterol 10 mcg qd in the first period, Olodaterol 20 mcg qd in the second period, Olodaterol 5 mcg qd in the third period, matching Placebo in the fourth period and Olodaterol 10 mcg qd in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P8">
          <title>Olo 10mcg / Olo 5mcg / Olo 20mcg / Olo 2mcg / Placebo</title>
          <description>Patients were administered Olodaterol 10 mcg qd in the first period, Olodaterol 5 mcg qd in the second period, Olodaterol 20 mcg qd in the third period, Olodaterol 2 mcg qd in the fourth period and matching Placebo in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P9">
          <title>Olo 20mcg / Placebo / Olo 10mcg / Olo 2mcg / Olo 5mcg</title>
          <description>Patients were administered Olodaterol 20 mcg qd in the first period, matching Placebo in the second period, Olodaterol 10 mcg qd in the third period, Olodaterol 2 mcg qd in the fourth period and Olodaterol 5 mcg qd in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
        <group group_id="P10">
          <title>Olo 20mcg / Olo 10mcg / Placebo / Olo 5mcg / Olo 2mcg</title>
          <description>Patients were administered Olodaterol 20 mcg qd in the first period, Olodaterol 10 mcg qd in the second period, matching Placebo in the third period, Olodaterol 5 mcg qd in the fourth period and Olodaterol 2 mcg qd in the fifth period. Olodaterol was administered via the Respimat inhaler.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (First Dose + Washout)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (Second Dose + Washout)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3 (Third Dose + Washout)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 4 (Fourth Dose + Washout)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 5 (Fifth Dose + Washout)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Total</title>
          <description>Total number of patients treated in the study. This was a double-blind, 5-period crossover trial. Each of the 36 patients received placebo and 4 single doses of Olodaterol (Olo) (2 microgram (mcg), 5 mcg, 10 mcg, 20mcg) separated by a wash-out period of at least 14 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.0" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Number of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) at 24 Hours After a Single-dose of Study Treatment</title>
        <description>Forced expiratory volume in one second (FEV1) at 24 hours after a single-dose of study treatment. Means are adjusted with test-day baseline, patient, treatment, and period as fixed effects. Test-day baseline value was defined as the value at 10 minutes before inhalation of study medication.</description>
        <time_frame>24 hours post-dosing</time_frame>
        <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data for FEV1 at 24 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) at 24 Hours After a Single-dose of Study Treatment</title>
          <description>Forced expiratory volume in one second (FEV1) at 24 hours after a single-dose of study treatment. Means are adjusted with test-day baseline, patient, treatment, and period as fixed effects. Test-day baseline value was defined as the value at 10 minutes before inhalation of study medication.</description>
          <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data for FEV1 at 24 hours.</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.916" spread="0.014"/>
                    <measurement group_id="O2" value="0.986" spread="0.014"/>
                    <measurement group_id="O3" value="1.015" spread="0.014"/>
                    <measurement group_id="O4" value="1.029" spread="0.014"/>
                    <measurement group_id="O5" value="1.035" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.070</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.031</ci_lower_limit>
            <ci_upper_limit>0.109</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.060</ci_lower_limit>
            <ci_upper_limit>0.138</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.113</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.074</ci_lower_limit>
            <ci_upper_limit>0.152</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.119</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.020</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.080</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC 0 - 3 Hours</title>
        <description>The FEV1 AUC was calculated as the area under the curve above zero as the horizontal axis from zero time to 3 hours, using the trapezoidal rule divided by 3 hours to give the results in litres. The test-day baseline (defined as the pulmonary function test (PFT) at 10 minutes before inhalation of study medication) was assigned to time zero.</description>
        <time_frame>-10 minutes (min), 30min, 1 hour (h), 2h and 3h post-dosing</time_frame>
        <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC 0 - 3 Hours</title>
          <description>The FEV1 AUC was calculated as the area under the curve above zero as the horizontal axis from zero time to 3 hours, using the trapezoidal rule divided by 3 hours to give the results in litres. The test-day baseline (defined as the pulmonary function test (PFT) at 10 minutes before inhalation of study medication) was assigned to time zero.</description>
          <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.997" spread="0.011"/>
                    <measurement group_id="O2" value="1.105" spread="0.011"/>
                    <measurement group_id="O3" value="1.152" spread="0.011"/>
                    <measurement group_id="O4" value="1.158" spread="0.011"/>
                    <measurement group_id="O5" value="1.189" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.108</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.139</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.155</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.124</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.161</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.130</ci_lower_limit>
            <ci_upper_limit>0.192</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.192</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.161</ci_lower_limit>
            <ci_upper_limit>0.223</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC 0 - 12 Hours</title>
        <description>The FEV1 AUC was calculated as the area under the curve above zero as the horizontal axis from zero time to 12 hours, using the trapezoidal rule divided by 12 hours to give the results in litres. The test-day baseline (defined as the pulmonary function test (PFT) at 10 minutes before inhalation of study medication) was assigned to time zero.</description>
        <time_frame>-10 minutes (min), 30min, 1 hour (h), 2h, 3h, 4h, 6h, 8h, 10h and 12h post-dosing</time_frame>
        <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC 0 - 12 Hours</title>
          <description>The FEV1 AUC was calculated as the area under the curve above zero as the horizontal axis from zero time to 12 hours, using the trapezoidal rule divided by 12 hours to give the results in litres. The test-day baseline (defined as the pulmonary function test (PFT) at 10 minutes before inhalation of study medication) was assigned to time zero.</description>
          <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.954" spread="0.012"/>
                    <measurement group_id="O2" value="1.053" spread="0.011"/>
                    <measurement group_id="O3" value="1.093" spread="0.011"/>
                    <measurement group_id="O4" value="1.108" spread="0.012"/>
                    <measurement group_id="O5" value="1.138" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.099</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.068</ci_lower_limit>
            <ci_upper_limit>0.131</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.139</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.107</ci_lower_limit>
            <ci_upper_limit>0.171</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.153</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.122</ci_lower_limit>
            <ci_upper_limit>0.185</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.184</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.152</ci_lower_limit>
            <ci_upper_limit>0.215</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC 0 - 24 Hours</title>
        <description>The FEV1 AUC was calculated as the area under the curve above zero as the horizontal axis from zero time to 24 hours, using the trapezoidal rule divided by 24 hours to give the results in litres. The test-day baseline (defined as the pulmonary function test (PFT) at 10 minutes before inhalation of study medication) was assigned to time zero.</description>
        <time_frame>-10 minutes (min), 30min, 1 hour (h), 2h, 3h, 4h, 6h, 8h, 10h, 12h, 14h, 22h, 23h and 24h post-dosing</time_frame>
        <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC 0 - 24 Hours</title>
          <description>The FEV1 AUC was calculated as the area under the curve above zero as the horizontal axis from zero time to 24 hours, using the trapezoidal rule divided by 24 hours to give the results in litres. The test-day baseline (defined as the pulmonary function test (PFT) at 10 minutes before inhalation of study medication) was assigned to time zero.</description>
          <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.923" spread="0.011"/>
                    <measurement group_id="O2" value="1.009" spread="0.011"/>
                    <measurement group_id="O3" value="1.040" spread="0.011"/>
                    <measurement group_id="O4" value="1.061" spread="0.011"/>
                    <measurement group_id="O5" value="1.085" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.087</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.056</ci_lower_limit>
            <ci_upper_limit>0.117</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.118</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.087</ci_lower_limit>
            <ci_upper_limit>0.148</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.138</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.107</ci_lower_limit>
            <ci_upper_limit>0.168</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.162</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.015</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.132</ci_lower_limit>
            <ci_upper_limit>0.193</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 AUC 12 - 24 Hours</title>
        <description>The FEV1 AUC was calculated as the area under the curve above zero as the horizontal axis from 12 hours to 24 hours, using the trapezoidal rule divided by 12 hours to give the results in litres. The test-day baseline (defined as the pulmonary function test (PFT) at 10 minutes before inhalation of study medication) was assigned to time zero.</description>
        <time_frame>12h, 14h, 22h, 23h and 24h post-dosing</time_frame>
        <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 AUC 12 - 24 Hours</title>
          <description>The FEV1 AUC was calculated as the area under the curve above zero as the horizontal axis from 12 hours to 24 hours, using the trapezoidal rule divided by 12 hours to give the results in litres. The test-day baseline (defined as the pulmonary function test (PFT) at 10 minutes before inhalation of study medication) was assigned to time zero.</description>
          <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.891" spread="0.012"/>
                    <measurement group_id="O2" value="0.965" spread="0.012"/>
                    <measurement group_id="O3" value="0.987" spread="0.012"/>
                    <measurement group_id="O4" value="1.014" spread="0.012"/>
                    <measurement group_id="O5" value="1.032" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.074</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.041</ci_lower_limit>
            <ci_upper_limit>0.108</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.096</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.062</ci_lower_limit>
            <ci_upper_limit>0.130</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.122</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.089</ci_lower_limit>
            <ci_upper_limit>0.156</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.141</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.017</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.107</ci_lower_limit>
            <ci_upper_limit>0.174</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 From 0 to 3 Hours</title>
        <description>Peak FEV1 was defined as the maximum values of FEV1 from 0 to 3 hours.</description>
        <time_frame>0 to 3 hours post-dosing</time_frame>
        <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 From 0 to 3 Hours</title>
          <description>Peak FEV1 was defined as the maximum values of FEV1 from 0 to 3 hours.</description>
          <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.043" spread="0.013"/>
                    <measurement group_id="O2" value="1.164" spread="0.013"/>
                    <measurement group_id="O3" value="1.209" spread="0.013"/>
                    <measurement group_id="O4" value="1.219" spread="0.014"/>
                    <measurement group_id="O5" value="1.256" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.121</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.084</ci_lower_limit>
            <ci_upper_limit>0.158</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.166</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.129</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.176</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.139</ci_lower_limit>
            <ci_upper_limit>0.214</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.213</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.019</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.176</ci_lower_limit>
            <ci_upper_limit>0.250</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Forced Vital Capacity (FVC) From 0 to 3 Hours</title>
        <description>Peak FVC was defined as the maximum values of FVC from 0 to 3 hours.</description>
        <time_frame>0 to 3 hours post-dosing</time_frame>
        <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Forced Vital Capacity (FVC) From 0 to 3 Hours</title>
          <description>Peak FVC was defined as the maximum values of FVC from 0 to 3 hours.</description>
          <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint</population>
          <units>L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.134" spread="0.035"/>
                    <measurement group_id="O2" value="3.440" spread="0.035"/>
                    <measurement group_id="O3" value="3.489" spread="0.035"/>
                    <measurement group_id="O4" value="3.485" spread="0.035"/>
                    <measurement group_id="O5" value="3.589" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.306</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.210</ci_lower_limit>
            <ci_upper_limit>0.402</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.355</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.258</ci_lower_limit>
            <ci_upper_limit>0.452</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.350</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.253</ci_lower_limit>
            <ci_upper_limit>0.447</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.455</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.049</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.359</ci_lower_limit>
            <ci_upper_limit>0.551</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Peak Bronchodilator Response</title>
        <description>A bronchodilator response was considered to have been achieved if an FEV1 measurement of at least 12% greater than the test-day baseline value was recorded at any time during the first 3 hours of observation after dosing.</description>
        <time_frame>0 to 3 hours post-dosing</time_frame>
        <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Peak Bronchodilator Response</title>
          <description>A bronchodilator response was considered to have been achieved if an FEV1 measurement of at least 12% greater than the test-day baseline value was recorded at any time during the first 3 hours of observation after dosing.</description>
          <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.0" spread="57.4"/>
                    <measurement group_id="O2" value="92.6" spread="55.1"/>
                    <measurement group_id="O3" value="98.6" spread="53.8"/>
                    <measurement group_id="O4" value="83.8" spread="46.6"/>
                    <measurement group_id="O5" value="96.9" spread="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Onset of Response</title>
        <description>Onset of the bronchodilator response after a single dose of study treatment was defined as the linear interpolation of the time of the first bronchodilator response and the time of the observation just prior to the first bronchodilator response (even if that is the baseline observation). If none of the FEV1 values in the first 3 hours after dosing exceeded 12% of the pre-dose value, then the onset was set to 3 hours plus 1 minute.</description>
        <time_frame>0 to 3 hours post-dosing</time_frame>
        <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Response</title>
          <description>Onset of the bronchodilator response after a single dose of study treatment was defined as the linear interpolation of the time of the first bronchodilator response and the time of the observation just prior to the first bronchodilator response (even if that is the baseline observation). If none of the FEV1 values in the first 3 hours after dosing exceeded 12% of the pre-dose value, then the onset was set to 3 hours plus 1 minute.</description>
          <population>Full Analysis Set (FAS): The FAS consisted of all treatment periods with baseline data and post-dosing data available for this endpoint.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.9" spread="56.2"/>
                    <measurement group_id="O2" value="91.5" spread="73.6"/>
                    <measurement group_id="O3" value="57.5" spread="68.5"/>
                    <measurement group_id="O4" value="59.9" spread="69.6"/>
                    <measurement group_id="O5" value="38.2" spread="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Rescue Medication on a Test-day</title>
        <description>Number of Patients Requiring Rescue Medication on a Test-day. Salbutamol inhalation aerosol MDI (Ventolin®, 100 μg/actuation) was provided for use as rescue medication. Administration of rescue medication can occur at any point during the pulmonary function testing as deemed necessary by the patient or the investigator.</description>
        <time_frame>Visits 1,2,4,5,6</time_frame>
        <population>Safety set which consisted of all randomised patients who had taken at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Rescue Medication on a Test-day</title>
          <description>Number of Patients Requiring Rescue Medication on a Test-day. Salbutamol inhalation aerosol MDI (Ventolin®, 100 μg/actuation) was provided for use as rescue medication. Administration of rescue medication can occur at any point during the pulmonary function testing as deemed necessary by the patient or the investigator.</description>
          <population>Safety set which consisted of all randomised patients who had taken at least one dose of study medication.</population>
          <units>Number of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</title>
        <description>Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).</description>
        <time_frame>2 weeks</time_frame>
        <population>Safety set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG</title>
          <description>Clinical relevant Abnormalities for Vital Signs, Blood Chemistry, Haematology, Urinalysis and ECG. New abnormal findings or worsenings of baseline conditions were reported as Adverse Events (cardiac disorders and investigations).</description>
          <population>Safety set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiac disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood bilirubin increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="2.9"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Testing: Average Change From Baseline of Potassium and Calcium</title>
        <description>Laboratory testing: Average change from baseline of potassium and calcium measured on test-days</description>
        <time_frame>Baseline and Visit 6</time_frame>
        <population>Safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O2">
            <title>Olo 2 mcg</title>
            <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Olo 5 mcg</title>
            <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O4">
            <title>Olo 10 mcg</title>
            <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
          </group>
          <group group_id="O5">
            <title>Olo 20 mcg</title>
            <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Testing: Average Change From Baseline of Potassium and Calcium</title>
          <description>Laboratory testing: Average change from baseline of potassium and calcium measured on test-days</description>
          <population>Safety set.</population>
          <units>mmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
                <count group_id="O5" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Potassium (N=17, 18, 17, 17, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" lower_limit="0.99" upper_limit="1.07"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.98" upper_limit="1.03"/>
                    <measurement group_id="O3" value="0.99" lower_limit="0.95" upper_limit="1.03"/>
                    <measurement group_id="O4" value="0.98" lower_limit="0.97" upper_limit="1.02"/>
                    <measurement group_id="O5" value="0.97" lower_limit="0.92" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (N=18, 18, 17, 17, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" lower_limit="0.99" upper_limit="1.03"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.99" upper_limit="1.03"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.98" upper_limit="1.01"/>
                    <measurement group_id="O4" value="1.01" lower_limit="1.00" upper_limit="1.03"/>
                    <measurement group_id="O5" value="1.01" lower_limit="0.99" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>Single dose including washout phase</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Single dose of matching placebo delivered by the Respimat inhaler.</description>
        </group>
        <group group_id="E2">
          <title>Olo 2 mcg</title>
          <description>Single dose of Olodaterol 2 mcg delivered by the Respimat inhaler.</description>
        </group>
        <group group_id="E3">
          <title>Olo 5 mcg</title>
          <description>Single dose of Olodaterol 5mcg delivered by the Respimat inhaler.</description>
        </group>
        <group group_id="E4">
          <title>Olo 10 mcg</title>
          <description>Single dose of Olodaterol 10 mcg delivered by the Respimat inhaler.</description>
        </group>
        <group group_id="E5">
          <title>Olo 20 mcg</title>
          <description>Single dose of Olodaterol 20 mcg delivered by the Respimat inhaler.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 9.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

